Dr. Marco Brughera
Chief Executive Officer and Global Head, Rare Disease
Dr. Brughera is Chief Executive Officer and Global Head, Rare Disease of Leadiant Biosciences S.p.A. Dr. Brughera has extensive experience in R&D, business development and general management particularly in the oncology and rare disease areas across several global pharmaceutical, rare disease and biotech companies.
From January 2011 through October 2012, Dr. Brughera was Corporate Research and Development Managing Director of the Sigma-Tau Group. From 2004 to 2010, he served as the Vice President of Preclinical Development at Nerviano Medical Sciences S.r.l. (“NMS Group”), a pharmaceutical oncology-focused integrated R&D company. He also served as the Managing Director at Accelera S.r.l., an independent contract research organization affiliated with the NMS Group. From 1999 to 2004, Dr. Brughera held several senior level positions in the areas of Discovery and Development with Pharmacia Corporation and Pfizer, Inc. Prior to 1999, he held various positions at Pharmacia & Upjohn, Kabi-Pharmacia and Farmitalia Carlo Erba.
Dr. Brughera earned his degree in Veterinary Medicine from the University of Milan and is a European Registered Toxicologist. He attended Management Courses at Thunderbird American Graduate Business School at Arizona State University and MIT. He was EFPIA deputy topic leader for the ICH review of the Oncology Therapeutic Guidance. Publication record includes more 60 publications/communications.
He is currently Board Member of the following publically traded companies: Soligenix, Inc., Fennec Pharmaceuticals, Inc., and Lee’s Pharmaceutical Holdings Ltd. He was Board Member at Gentium from December 2011 to January 2014.